Pluri Inc. (PLUR) - Q2 2025 (Six Months Ended Dec 31, 2024) Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the six-month period ended December 31, 2024 (Q2 of Fiscal Year 2025). Pluri Inc. is a biotechnology company operating in regenerative medicine, immunotherapy, food technology, and agricultural technology. The company utilizes a 3D cell expansion platform and operates a Contract Development and Manufacturing Organization (CDMO). The company is a smaller reporting company and is currently in discussions regarding the restructuring of a significant loan from the European Investment Bank (EIB).
Key Financial Metrics
| Metric | Six Months Ended Dec 31, 2024 | Six Months Ended Dec 31, 2023 |
|---|---|---|
| Revenue | $511,000 | $159,000 |
| Cost of Revenues | $200,000 | $0 |
| Gross Profit | $311,000 | $159,000 |
| Operating Loss | $(10,155,000) | $(10,590,000) |
| Net Loss | $(9,146,000) | $(10,092,000) |
| Net Loss Attributable to Shareholders | $(8,838,000) | $(9,866,000) |
| Loss Per Share (Basic & Diluted) | $(1.61) | $(1.92) |
| Cash and Cash Equivalents | $7,229,000 | $5,468,000 |
| Total Cash, Deposits & Restricted Cash | $22,374,000 | $15,300,000 (approx. based on prior period) |
| Working Capital | $17,930,000 | N/A |
| Long-Term Debt (EIB Loan) | $23,798,000 | $24,027,000 |
| Shareholders' Equity (Deficit) | $(8,028,000) | $4,399,000 |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 221% year-over-year (YoY) to $511,000, driven by the launch of the CDMO business and increased activity in agricultural technology (AgTech) collaborations.
- Expense Reduction: Net R&D expenses decreased 2% YoY to $5.81 million due to headcount reductions (10 R&D employees) and supplier credits. General and Administrative (G&A) expenses decreased 3% YoY to $4.65 million, despite CEO salary reinstatement, due to lower share-based compensation amortization.
- Financial Income: Other financial income increased significantly to $1.44 million (from $0.93 million) primarily due to foreign currency translation gains related to the EIB loan (USD vs. Euro fluctuations).
- Equity Position: The company moved from positive shareholders' equity ($96,000) at the end of the prior fiscal year to a deficit of $(8.03 million) due to the current period's net loss.
Outlook, Risks, and Subsequent Events
- Capital Raising (Subsequent Events):
- Private Placement 1: Closed Feb 5, 2025, raising $6.5 million from Mr. Alejandro Weinstein (1.38M shares + warrants). Mr. Weinstein appointed to the Board.
- Private Placement 2: Agreed Feb 3, 2025, with Merchant Adventure Fund L.P. for approx. $3.5 million (759k shares + warrants).
- Strategic Acquisition: Entered a binding term sheet to acquire approx. 71% of Kokomodo Ltd. (cultivated cocoa) for $4.5 million in shares. Closing expected Q2 2025 pending shareholder approval.
- Nasdaq Compliance Risk: Received a deficiency letter on Nov 25, 2024, for failing to meet the $2.5 million shareholders' equity requirement. Granted an extension until May 24, 2025, to regain compliance. Failure to comply may result in delisting.
- Geopolitical Risk: Operations are based in Haifa, Israel. Ongoing conflict in the region poses risks to operations, employee availability (reserve duty), and supply chains, though operations are currently functioning.
- Debt Restructuring: The company is in discussions with the EIB regarding the restructuring of a €20 million loan (approx. $23.8M principal + interest) due June 2026. No certainty of restructuring exists.
Investor Verification Checklist
- Nasdaq Compliance: Verify if the company meets the $2.5M equity requirement by the May 24, 2025 deadline to avoid delisting.
- Cash Runway: Confirm the utilization of the $10M+ raised in subsequent private placements and whether it extends the runway beyond the current 12-month projection.
- EIB Loan Status: Monitor the outcome of discussions regarding the restructuring of the €20M EIB loan due in 2026.
- Kokomodo Transaction: Track shareholder approval status and closing of the Kokomodo acquisition, noting the fallback provisions if the deal fails.
- Revenue Sustainability: Assess the durability of CDMO and AgTech revenue streams, which are currently the primary drivers of the $511k revenue figure.